Want to see HK:6855 full AI Analyst Report?
Top Page
Ascentage Pharma Group International
(6855)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$32.00
▼(-37.13% Downside)
Action:Reiterated
Date:05/04/26
The score is held back primarily by continued heavy losses and accelerating cash burn, despite strong revenue growth and high gross margins. Technicals also remain weak with the stock trading below key moving averages and negative momentum; valuation support is limited given negative earnings and no dividend.
Positive Factors
Revenue Growth
Accelerating revenue (≈43% in 2025) indicates strengthening commercial or clinical activity and growing validation of the company’s programs. Sustained top-line momentum can support later-stage trials, attract partners, and improve cash‑generation prospects once products commercialize.
Negative Factors
Deep Losses
Extremely negative margins and ROE show the business remains far from profitability. Persistent large losses erode equity, lengthen time to self‑funding, and make long‑term returns dependent on successful trials or costly capital raises, raising structural execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Accelerating revenue (≈43% in 2025) indicates strengthening commercial or clinical activity and growing validation of the company’s programs. Sustained top-line momentum can support later-stage trials, attract partners, and improve cash‑generation prospects once products commercialize.
Read all positive factors
Ascentage Pharma Group International (6855) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$12.30B
Dividend YieldN/A
Average Volume (3M)2.29M
Price to Earnings (P/E)―
Beta (1Y)0.80
Revenue Growth-41.32%
EPS Growth-159.81%
CountryHK
Employees567
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.46
Shares Outstanding373,555,760
10 Day Avg. Volume1,948,642
30 Day Avg. Volume2,293,783
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)12.61
Price to Sales (P/S)29.89
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$65.76Price Target Upside29.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.42
Revenue Forecast (FY)HK$916.70M
Ascentage Pharma Group International Business Overview & Revenue Model
Company Description
Ascentage Pharma Group International is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative therapies for various cancers, chronic hepatitis B virus (HBV), and age-related conditions. Its operations are conce...
How the Company Makes Money
null...
Ascentage Pharma Group International Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 559.26M | 980.65M | 221.98M | 209.71M | 27.91M |
| Gross Profit | 427.35M | 951.57M | 191.44M | 187.71M | 24.58M |
| EBITDA | -1.10B | -299.63M | -743.61M | -835.99M | -915.99M |
| Net Income | -1.21B | -405.43M | -925.64M | -882.92M | -782.42M |
Balance Sheet | |||||
| Total Assets | 3.97B | 2.62B | 2.50B | 2.83B | 2.94B |
| Cash, Cash Equivalents and Short-Term Investments | 2.47B | 1.26B | 1.10B | 1.50B | 1.75B |
| Total Debt | 1.98B | 1.67B | 1.80B | 1.79B | 1.08B |
| Total Liabilities | 2.63B | 2.34B | 2.43B | 2.42B | 1.71B |
| Stockholders Equity | 1.33B | 264.19M | 60.42M | 408.66M | 1.23B |
Cash Flow | |||||
| Free Cash Flow | -1.20B | -135.65M | -782.92M | -857.20M | -1.04B |
| Operating Cash Flow | -1.17B | -111.36M | -726.08M | -653.91M | -604.68M |
| Investing Cash Flow | -1.00B | -362.04M | 21.92M | -384.61M | -466.52M |
| Financing Cash Flow | 2.54B | 314.77M | 368.75M | 619.27M | 1.78B |
Ascentage Pharma Group International Technical Analysis
Negative
50.90
Price Trends
39.93
Negative
43.36
Negative
54.16
Negative
Market Momentum
-2.43
Negative
30.24
Neutral
16.64
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6855, the sentiment is Negative. The current price of 50.9 is above the 20-day moving average (MA) of 33.87, above the 50-day MA of 39.93, and below the 200-day MA of 54.16, indicating a bearish trend. The MACD of -2.43 indicates Negative momentum. The RSI at 30.24 is Neutral, neither overbought nor oversold. The STOCH value of 16.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6855.
Ascentage Pharma Group International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$17.73B | 25.61 | 10.12% | ― | 110.05% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$16.42B | -11.22 | -24.29% | ― | 8.50% | 35.24% | |
47 Neutral | HK$8.67B | -23.59 | -6.91% | ― | 142.64% | 72.20% | |
44 Neutral | HK$12.30B | -8.30 | -123.74% | ― | -41.32% | -159.81% | |
44 Neutral | HK$8.59B | -68.31 | -11.21% | ― | 219.26% | 87.63% | |
41 Neutral | HK$7.43B | -19.39 | -64.78% | ― | -33.37% | -344.90% |
* Healthcare Sector Average
HK:6855
Ascentage Pharma Group International
33.20
-44.90
-57.49%
HK:9688
Zai Lab Ltd
14.46
-12.99
-47.32%
HK:9969
InnoCare Pharma Ltd.
11.86
-1.24
-9.47%
HK:1952
Everest Medicines Ltd.
24.50
-39.25
-61.57%
HK:2171
CARsgen Therapeutics Holdings Ltd.
14.26
-8.84
-38.27%
HK:2616
CStone Pharmaceuticals
4.71
0.52
12.41%
Ascentage Pharma Group International Corporate Events
Ascentage Pharma Grants New RSUs to 453 Employees Under 2021 Scheme
Jun 29, 2026
Ascentage Pharma Group International has approved a further grant of restricted share units under its 2021 RSU Scheme, issuing 440,743 RSUs to 453 employees of the Group. The awards, which require no purchase price from recipients, will be satisfi...
Ascentage Pharma Showcases Broad Leukemia Data for Olverembatinib and Lisaftoclax at EHA2026
Jun 14, 2026
Ascentage Pharma reported 17 clinical updates at the European Hematology Association Congress, highlighting progress for its key drugs olverembatinib and lisaftoclax in multiple blood cancers. The data underscore the company’s strategy to mo...
Ascentage Pharma Trustee Buys Shares to Fund 2022 RSU Scheme
Jun 11, 2026
Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme has purchased 110,000 existing shares on the open market to satisfy future RSU vesting obligations. The shares, acquired on 11 June 2026...
Ascentage Pharma Trustee Buys Shares to Fund 2022 RSU Incentive Scheme
Jun 10, 2026
Ascentage Pharma Group International has disclosed that the trustee of its 2022 restricted share unit scheme purchased 190,000 existing shares on the market on June 10, 2026, representing about 0.0509% of issued share capital, at an average price ...
Ascentage Pharma Trustee Buys Shares to Fund 2022 RSU Scheme
May 28, 2026
Ascentage Pharma Group International has disclosed that its trustee purchased 50,000 existing shares on the market on May 28, 2026, for about HK$1.91 million to support its 2022 Restricted Share Unit Scheme. These shares, representing roughly 0.01...
Ascentage Pharma Adds 100,000 Shares to 2022 RSU Trust in Latest On‑Market Buy
May 27, 2026
Ascentage Pharma Group International has disclosed that the trustee of its 2022 RSU Scheme purchased 100,000 existing shares on the market on May 27, 2026, for about HK$3.98 million, representing roughly 0.0268% of the company’s issued share...
Ascentage Pharma Sheds Biotech Marker After Meeting HKEX Revenue and Market Cap Tests
May 27, 2026
Ascentage Pharma Group International has secured Hong Kong Stock Exchange approval to dis-apply specific biotech listing rules, reflecting its transition from a pre-revenue style biotech listing to a company meeting the standard market capitalizat...
Ascentage Pharma Showcases Promising Olverembatinib Data in Multiple Leukemia Trials at ASCO 2026
May 22, 2026
Ascentage Pharma has disclosed new clinical data from six studies selected for the 2026 American Society of Clinical Oncology Annual Meeting, underscoring progress in its core oncology pipeline. Three abstracts, including two on its BCR-ABL inhibi...
Ascentage Pharma Shareholders Approve All Resolutions at 2026 AGM
May 20, 2026
Ascentage Pharma shareholders approved all resolutions at the 2026 annual general meeting, including adoption of the 2025 audited financial statements, re-election of several non-executive and independent directors, authorization for the board to ...
Ascentage Pharma Adds Executive Equity Grants to AGM Agenda and Updates Proxy Process
Apr 30, 2026
Ascentage Pharma Group International has issued a supplemental notice confirming that its annual general meeting will proceed as scheduled in Suzhou on May 20, 2026, while adding two new ordinary resolutions. Shareholders will be asked to approve ...
Ascentage Pharma Sets AGM to Approve 2025 Accounts, Board Mandates and Share Issue Authority
Apr 28, 2026
Ascentage Pharma Group International has called its annual general meeting for May 20, 2026, in Suzhou, China, where shareholders will vote on key corporate matters, including adoption of the 2025 audited financial statements and reports. The meet...
Ascentage Pharma to Showcase Six Cancer Drug Studies at 2026 ASCO Meeting
Apr 21, 2026
Ascentage Pharma will present data from six clinical studies involving three key drug candidates at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, underscoring the company’s growing presence in cutting-edge cancer ...
Ascentage Pharma Grants New RSUs to Top Executives Under 2022 Incentive Scheme
Apr 20, 2026
Ascentage Pharma has granted 696,263 restricted share units under its 2022 RSU Scheme to three senior personnel, including CEO and executive director Dr. Yang Dajun, chief medical officer and substantial shareholder Dr. Zhai Yifan, and a senior ma...
Ascentage Pharma Showcases Promising Combination Oncology Data at AACR 2026
Apr 19, 2026
Ascentage Pharma Group International will present four preclinical studies at the American Association for Cancer Research 2026 Annual Meeting, highlighting three key drug candidates: olverembatinib, APG-2449, and APG-5918. The data underscore the...
Ascentage Pharma Relocates Hong Kong Principal Office and Highlights Global Governance Standards
Apr 1, 2026
Ascentage Pharma Group International has changed its principal place of business in Hong Kong to Unit 906, 9/F., Haleson Building, 1 Jubilee Street, Central, effective April 1, 2026. The move, approved and announced by the board of directors, may ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.